Hohimer Wealth Management’s ANI Pharmaceuticals ANIP Stock Holding History

Hohimer Wealth Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$289K	Buy	3,496 +15	+0.4%	+$1.2K	0.03%	279
2026 Q1	$268K	Buy	3,481 +51	+1%	+$3.98K	0.03%	248
2025 Q4	$271K	Sell	3,430 -39	-1%	-$3.38K	0.04%	230
2025 Q3	$318K	Sell	3,469 -1,417	-29%	-$116K	0.04%	223
2025 Q2	$319K	Sell	4,886 -103	-2%	-$6.71K	0.06%	179
2025 Q1	$334K	Buy	4,989 +247	+5%	+$14.8K	0.07%	188
2024 Q4	$262K	Buy	4,742 +319	+7%	+$18.3K	0.05%	197
2024 Q3	$264K	Buy	+4,423	New	+$270K	0.06%	183

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hohimer Wealth Management's ANIP Position: Q2 2026 in Review

Hohimer Wealth Management increased its ANI Pharmaceuticals (ANIP) stake by 0.43% in Q2 2026, buying an estimated $1.2K and bringing the position to 3,496 shares worth $289K. The position accounts for 0.03% of the portfolio, ranked #279.

Hohimer Wealth Management first reported a position in ANIP in Q3 2024 and has held it in 8 quarters since. The position peaked at $334K in Q1 2025. 308 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Hohimer Wealth Management held 3,496 shares of ANI Pharmaceuticals worth $289K as of Q2 2026.
Hohimer Wealth Management bought 15 ANI Pharmaceuticals shares in Q2 2026, an estimated $1.2K.
ANI Pharmaceuticals made up 0.03% of Hohimer Wealth Management's portfolio in Q2 2026, its #279 holding.
Hohimer Wealth Management first reported a position in ANI Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
Hohimer Wealth Management's ANI Pharmaceuticals position peaked at $334K in Q1 2025.
308 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Hohimer Wealth Management's 13F filing for Q2 2026, filed 3 Aug 2026.